Evidence map›Paper›PMID 27522264›Full record

ArticleAtherosclerosis2016

Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.

Gunnar Gudmundsson, Olof Birna Margretardottir, Martin Ingi Sigurdsson, Tamara B Harris, Lenore J Launer, Sigurdur Sigurdsson, Orn Olafsson, Thor Aspelund, Vilmundur Gudnason

Abstract read
In one paragraph

Article in Atherosclerosis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Gunnar GudmundssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Respiratory Medicine and Sleep, Landspitali National University Hospital, Reykjavik, Iceland. Electronic address: ggudmund@landspitali.is.
Olof Birna MargretardottirFaculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Martin Ingi SigurdssonDepartment of Anesthesia, Perioperative and Pain Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States.
Tamara B HarrisLaboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, United States.
Lenore J LaunerLaboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, United States.
Sigurdur SigurdssonThe Icelandic Heart Association, Kopavogur, Iceland.
Orn OlafssonThe Icelandic Heart Association, Kopavogur, Iceland.
Thor AspelundFaculty of Medicine, University of Iceland, Reykjavik, Iceland; The Icelandic Heart Association, Kopavogur, Iceland.
Vilmundur GudnasonFaculty of Medicine, University of Iceland, Reykjavik, Iceland; The Icelandic Heart Association, Kopavogur, Iceland.
Icelandic Heart Association · ISNational Institute on Aging · USBrigham and Women's Hospital · USNational University Hospital of Iceland · ISSahlgrenska University Hospital · SEUniversity of Iceland · IS

Funding

AGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–
NIA NIH HHS N01 AG012100
6 · The paper itself

Abstract

BACKGROUND AND

aimsAirflow limitation, i.e. reduced forced expiratory volume in 1-s (FEV1), is associated with increased prevalence of atherosclerosis, however, causal mechanisms remain elusive. The objective of the study was to determine if the association between airflow obstruction and markers of atherosclerosis is mediated by systemic inflammation.

methods1154 subjects from the longitudinal AGES Reykjavik study were included. Population characteristics, systemic inflammation markers from blood (white blood cell counts (WBC) and level of C-reactive protein (CRP)) were compared between patients with and without airflow limitation defined by reduced FEV1 on spirometry. Atherosclerosis burden was quantified by measurements of coronary artery calcium, aortic arch and distal aortic calcification in addition to carotid intimal media thickness (CIMT).

resultsSubjects were split into four groups according to smoking status and whether airflow limitation was present. There was a higher overall burden of atherosclerosis in ever-smokers compared to never-smokers, and in individuals with airflow obstruction compared to individuals without airflow obstruction. After adjusting for population characteristics, Framingham cardiovascular risk factors and markers of systemic inflammation (WBC and CRP), there was a significantly increased aortic arch and distal aorta calcification and higher CIMT measurement in individuals with airflow obstruction compared to individuals without airflow obstruction. After adjusting for population characteristics, Framingham cardiovascular risk factors and markers of systemic inflammation (WBC and CRP), there was a significantly increased aortic arch and distal aorta calcification and higher CIMT measurement in individuals with airflow obstruction compared to individuals without airflow obstruction.

conclusionsSystemic inflammation (WBC and CRP) does not appear to mediate the association between airflow limitation and atherosclerosis. Only airflow limitation and not systemic inflammation (WBC and CRP) appears to be an independent predictor of atherosclerosis.

Indexed as

AgedAged, 80 and overAge FactorsAgingAirway ObstructionAortaAtherosclerosisBrain InfarctionCalcinosisCardiovascular DiseasesCarotid Intima-Media ThicknessCoronary VesselsC-Reactive ProteinFemaleHumansIcelandC-Reactive ProteinAtherosclerosisCardiovascular risk factorsChronic obstructive pulmonary diseaseSystemic inflammation

Identifiers

PMID27522264
PMCPMC5963694
OpenAlexW2488048468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.